Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL530570 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL2352340 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL8518463 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL5384786 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL8601641 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL1921958 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL1925892 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL433597 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL717375 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL534555 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318957-B2 | Antitumor agents; High yield and High purity Docetaxel; without chromatographic purifications; by reaction with di-tert-butyl dicarbonate in solvents such as alcohols in the absence of bases; crystallizations; esterification; hydrolysis; acidification | INDENA S.P.A. (IT) | 2012-11-27 | — | — | US | disclosed |
| US-7446126-B2 | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel | INDENA S.P.A. (IT) | 2008-11-04 | — | — | US | disclosed |
| US-20080200700-A1 | SEMISYNTHESIS PROCESS FOR THE PREPARATION OF 10 DEACETYL-N-DEBENZOYL-PACLITAXEL | INDENA S.P.A. (IT) | 2008-08-21 | — | — | US | disclosed |
| EP-1712552-A1 | Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel | INDENA S.p.A. (IT) | 2006-10-18 | — | — | EP | disclosed |
| US-20060079571-A1 | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel | INDENA S.P.A. (IT) | 2006-04-13 | — | — | US | disclosed |
| US-4822804-A | 5,6,7,-trinor-4,8-inter-m-phenylene 2-nor PGI2 derivatives and anti-ulcer, anti-thrombotic and anti-hypertensive pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079571-A1 | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel | DHPS, SIRT6, HDAC11 | ESR1 4201/4885MEN1 632/4885KMT2A 1908/4885 |
| US-20080200700-A1 | SEMISYNTHESIS PROCESS FOR THE PREPARATION OF 10 DEACETYL-N-DEBENZOYL-PACLITAXEL | DHPS, SIRT6, HDAC6 | ESR1 4069/4885MEN1 676/4885KMT2A 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.